Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma
- 1 August 2026
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (8) , e2501261
Abstract
PURPOSE: Isocitrate dehydrogenase 1 and 2 ( IDH1 and IDH2 ) mutations are common in intrahepatic cholangiocarcinoma (ICC), but their prognostic value is unclear. Using a large data set, we assessed their impact in resected and nonresected ICC. METHODS: Adults from two medical centers (MSKCC and Erasmus) with ICC treated with curative-intent resection (resected) or managed nonoperatively (unresectable) who underwent next-generation sequencing were analyzed retrospectively. Kaplan-Meier and Cox regressions assessed the impact of IDH status on outcomes. RESULTS: Of the 795 patients analyzed, 25% had IDH1/2 mutations ( IDH mut) and 43% underwent resection. Median overall survival (OS) of the cohort was 32 months in IDH mut and 28 months for IDH wt ( P = .2). High-risk genetic alterations ( TP53 mut, KRAS mut, and CDKN2A del) were more frequent in IDH wild-type ( IDH wt; odds ratio, 2.26; q < 0.001). OS was 19 months in patients with high-risk alterations versus 40 months in patients without ( P < .001). In resected patients, recurrence-free survival (RFS) in IDH mut was 20 months versus 14 months for IDH wt ( P = .018), and OS was 69 months versus 50 months, respectively ( P = .2). However, after controlling for high-risk alterations, the potential benefit of IDH mut was no longer apparent (RFS: hazard ratio [HR], 0.78; P = .095; OS: HR, 0.88; P = .4). In unresectable IDH mut patients, progression-free survival was 9.4 months versus 9.1 months for IDH wt ( P = .7), and OS was 22 months versus 18 months, respectively ( P = .13). There remained no differences after controlling for high-risk alterations. IDH status was not a significant survival predictor in multivariable models. CONCLUSION: In this cohort of patients with ICC, IDH mut was not an independent predictor of survival, after controlling for high-risk alterations and clinical variables. IDH mutational status alone should, therefore, not be used to guide prognosis.Keywords
This publication has 25 references indexed in Scilit:
- Epidemiology of cholangiocarcinomaEuropean Journal of Surgical Oncology, 2023
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary centerJournal of Cancer Research and Clinical Oncology, 2023
- Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic StudiesJAMA Oncology, 2022
- Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic CholangiocarcinomaJAMA Surgery, 2021
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 MutationJAMA Oncology, 2021
- Genetic Determinants of Outcome in Intrahepatic CholangiocarcinomaHepatology, 2021
- Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencingExperimental and Molecular Pathology, 2015
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2010